文献速递心脑血管急症重症综合管理与镇静镇痛

血流储备分数指导的PCI与冠状动脉旁路移植术的比较

Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
PubMed 文献 · N Engl J Med · 2021-11-04
一句话结论三支冠状动脉病变患者中,FFR指导的PCI在1年主要不良心脑血管事件上未能证明不劣于CABG(HR 1.5,95%CI 1.1-2.2)。

FAME 3为多中心、国际、非劣效性随机试验,纳入1500例三支冠状动脉病变患者,在48个中心随机分配至CABG或FFR指导的PCI(使用当代佐他莫司洗脱支架)。主要终点为1年内主要不良心脑血管事件(全因死亡、心肌梗死、卒中或再次血运重建)。FFR指导PCI组1年主要终点发生率为10.6%,CABG组为6.9%(HR 1.5;95%CI 1.1-2.2),不符合非劣效性(非劣效性P=0.35)。死亡、心肌梗死或卒中复合终点在PCI组为7.3%、CABG组为5.2%(HR 1.4;95%CI 0.9-2.1)。大出血、心律失常和急性肾损伤在CABG组发生率更高。

要点

  • 三支冠状动脉病变患者中,FFR指导PCI组1年主要不良心脑血管事件发生率为10.6%,CABG组为6.9%(HR 1.5;95%CI 1.1-2.2),未达非劣效性。
  • 非劣效性预设界值为风险比95%CI上限小于1.65,实际上限为2.2,非劣效性P=0.35,未证明FFR指导PCI不劣于CABG。
  • 死亡、心肌梗死或卒中复合终点:FFR指导PCI组7.3%,CABG组5.2%(HR 1.4;95%CI 0.9-2.1)。
  • 安全性方面,大出血、心律失常和急性肾损伤在CABG组发生率高于FFR指导PCI组。
  • FFR指导PCI组平均置入3.7±1.9枚支架,CABG组平均3.4±1.0个远端吻合口。

适用人群与场景

  • 三支冠状动脉病变患者,在48个中心随机分配至CABG或FFR指导的PCI。

诊断标准与关键阈值

  • 非劣效性界值:FFR指导PCI对比CABG的风险比95%CI上限小于1.65。
  • 主要终点:1年内主要不良心脑血管事件,定义为全因死亡、心肌梗死、卒中或再次血运重建。

处置流程与药物剂量

  • FFR指导PCI组使用当代佐他莫司洗脱支架,平均置入3.7±1.9枚支架。
  • CABG组平均完成3.4±1.0个远端吻合口。
  • 原文未提及具体药物剂量、给药途径、频次或目标值。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 多中心、国际、非劣效性随机试验,1500例患者,48个中心,比较CABG与FFR指导PCI(佐他莫司洗脱支架)。
  • 主要终点1年主要不良心脑血管事件:FFR指导PCI组10.6%,CABG组6.9%(HR 1.5;95%CI 1.1-2.2),非劣效性P=0.35,未达非劣效。
  • 次要终点死亡、心肌梗死或卒中:FFR指导PCI组7.3%,CABG组5.2%(HR 1.4;95%CI 0.9-2.1)。
  • 安全性:大出血、心律失常和急性肾损伤在CABG组发生率高于FFR指导PCI组。

证据类型、等级与局限

  • 证据类型:多中心、国际、非劣效性随机对照试验(RCT)。
  • 局限:原文未明确提及;设计上为非劣效性试验,主要终点未达非劣效。

对床旁实践的改变

  • 在三支冠状动脉病变患者中,FFR指导PCI在1年主要不良心脑血管事件上未证明不劣于CABG,支持CABG作为该类患者的优先血运重建策略。
  • FFR指导PCI组大出血、心律失常和急性肾损伤发生率低于CABG组,可用于权衡短期安全性风险。
  • 原文未提及适用与不适用人群的具体标准,临床决策需结合患者个体情况。

指南或共识出处

  • FAME 3试验(ClinicalTrials.gov number, NCT02100722),由Medtronic和Abbott Vascular资助。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Patients with three-vessel coronary artery disease have been found to have better outcomes with coronary-artery bypass grafting (CABG) than with percutaneous coronary intervention (PCI), but studies in which PCI is guided by measurement of fractional flow reserve (FFR) have been lacking.

METHODS: In this multicenter, international, noninferiority trial, patients with three-vessel coronary artery disease were randomly assigned to undergo CABG or FFR-guided PCI with current-generation zotarolimus-eluting stents. The primary end point was the occurrence within 1 year of a major adverse cardiac or cerebrovascular event, defined as death from any cause, myocardial infarction, stroke, or repeat revascularization. Noninferiority of FFR-guided PCI to CABG was prespecified as an upper boundary of less than 1.65 for the 95% confidence interval of the hazard ratio. Secondary end points included a composite of death, myocardial infarction, or stroke; safety was also assessed.

RESULTS: A total of 1500 patients underwent randomization at 48 centers. Patients assigned to undergo PCI received a mean (±SD) of 3.7±1.9 stents, and those assigned to undergo CABG received 3.4±1.0 distal anastomoses. The 1-year incidence of the composite primary end point was 10.6% among patients randomly assigned to undergo FFR-guided PCI and 6.9% among those assigned to undergo CABG (hazard ratio, 1.5; 95% confidence interval [CI], 1.1 to 2.2), findings that were not consistent with noninferiority of FFR-guided PCI (P = 0.35 for noninferiority). The incidence of death, myocardial infarction, or stroke was 7.3% in the FFR-guided PCI group and 5.2% in the CABG group (hazard ratio, 1.4; 95% CI, 0.9 to 2.1). The incidences of major bleeding, arrhythmia, and acute kidney injury were higher in the CABG group than in the FFR-guided PCI group.

CONCLUSIONS: In patients with three-vessel coronary artery disease, FFR-guided PCI was not found to be noninferior to CABG with respect to the incidence of a composite of death, myocardial infarction, stroke, or repeat revascularization at 1 year. (Funded by Medtronic and Abbott Vascular; FAME 3 ClinicalTrials.gov number, NCT02100722.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Fearon, Zimmermann, De Bruyne, et al. Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery. N Engl J Med. 2021. PMID: 34735046. doi:10.1056/NEJMoa2112299

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。